The contribution of IL-I to leukocyte infiltration in anti-glomerular basement membrane (GBM) antibody (Ab) glomerulonephritis (GN) was examined by the administration of a specific IL-i receptor antagonist (IL-lra). Lewis rats received anti-GBM Ab or normal rabbit serum and were treated with either 0.9% saline or 6 mg IL-ira over a 24-h time period. Plasma IL-Ira concentration was 2,659±51 ng/ml 4 h after anti-GBM Ab and IL-lra administration. PMN and monocyte/macrophage infiltration declined 39% (9.8±1.9 to 6.0±1.5 PMN/glomerulus, P < 0.001) and 29% (4.9±0.8 to 3.5±0.8 ED-I cells/glomerulus, P = 0.002) with IL-ira treatment at 4 h, respectively. Similarly, the number of glomerular cells staining for lymphocyte function-associated molecule-lo (CD18) declined 39% from 16.7±1.9 to 10.7±1.6 cells/glomerulus at 4 h (P = 0.0001). This was associated with a decrease in glomerular intracellular adhesion molecule-i expression. The mean glomerular intracellular adhesion molecule-i score in anti-GBM Ab GN rats treated with IL-ira was less than that of rats administered anti-GBM Ab and 0.9% saline at 4 (2.0±0.2 vs 2.5±0.2, P < 0.05) and 24 (2.5±0.1 vs 3.1±0.2, P = 0.0001 ) h. These immunopathologic changes correlated with a 50% reduction in proteinuria from 147±34 to 75±25 mg/d (P < 0.002). Treatment with IL-ira did not affect the steady state mRNA expression of either IL-il& or TNFa. An increase in the
Receivedfor publication 14 January 1993 and in revisedform 26 July 1993. early stages of inflammation in anti-glomerular basement membrane (GBM)' antibody (Ab)-induced glomerulonephritis (GN) (1) (2) (3) . Among its many actions, IL-I may contribute to the prominent leukocyte infiltration in anti-GBM Ab GN (4) . The latter process depends on specific interactions between adhesion molecules and their ligands present on leukocyte and endothelial cell surfaces. IL-1 promotes leukocyte adhesion by inducing the de novo synthesis of adhesion molecules by endothelial cells, as well as by increasing the affinity of the corresponding leukocyte ligands (5) .
Of the numerous cell adhesion molecules, we chose to study the interaction between lymphocyte function-associated molecule-I (LFA-1, CD 1 a/CD 1 8) and its ligand, intracellular adhesion molecule-1 (ICAM-1 ), because of the availability of specific monoclonal antibodies. LFA-1 is a cell adhesion molecule whose expression is limited to leukocytes. It is a member of the integrin family and is constitutively expressed on PMNs, B and T lymphocytes (5) , and most monocytes, with the exception of some tissue macrophages (6, 7) . Monocytes, but not PMNs, can increase LFA-1 expression twofold in response to CSa, leukotriene B4, and TNF (8) . By comparison, ICAM-1 can be expressed on a wide variety of cells including mesangial (9) and glomerular endothelial cells (10) . The low basal expression of ICAM-1 on vascular endothelial cells is rapidly upregulated by cytokines, including IL-1, TNF, and interferon y ( 1 1, 12) .
The cloning and expression ofa specific IL-1 receptor antagonist (IL-lra) offer an opportunity to study the role of IL-1 on leukocyte accumulation in anti-GBM Ab GN. The recombinant IL-1ra, a 17-kD protein, competes with IL-1 for binding to its receptors and, in doing so, blocks the activity of IL-1 ( 13 ) . Two families of IL-1 receptors have been identified. The IL-1 type I receptor is an 80-kD protein present on T cells, fibroblast, and endothelial cells ( 14, 15 ), while the type II receptor is a 68-kD protein found on B cells, macrophages, and neutrophils (16) . The IL-I ra differs in its ability to block the binding of IL-1 to these two receptors. It blocks binding to the type I receptor at nearly equimolar concentrations, whereas a 10-50-M excess is required to block its binding to type II receptors (4) . Nonetheless, the administration of IL-1 ra can attenuate a number of systemic responses associated with inflammation ( 17 ). This study was undertaken to examine whether selective blockade of IL-1 receptors could reduce the severity of anti-GBM Ab GN, an effect which might involve selective re-duction of leukocyte infiltration by interfering with IL-1-associated effects on inflammatory cell adhesion.
Methods
Preparation of anti-GBM Ab and normal rabbit serum (NRS). Anti-GBM Ab was prepared by immunizing New Zealand White rabbits with rat GBM as described previously ( 18) . NRS was obtained by bleeding naive, unimmunized rabbits. Nanogram quantities of endotoxin present within the anti-GBM Ab and NRS were removed by incubation of the serum with Pyrofree III endotoxin affinity matrix (Alerchek, Inc., Portland, ME). Endotoxin was not detected by the limulus amoebocyte assay at concentrations above 3 pg/ml in either the anti-GBM Ab or NRS after Pyrofree III treatment.
Experimental design. Female Lewis rats (The Scripps Research Institute Breeding Colony) weighing 150-170 g were used for these experiments. A 24-h urine was collected to quantitate baseline proteinuria on day 1. The animals were divided into four groups, with group I (n = 11) receiving anti-GBM Ab (0.5 ml) intravenously and 0.9% saline vehicle subcutaneously. Group II (n = 11 ) rats were given anti-GBM Ab (0.5 ml) and the IL-lra in 0.9% saline. Groups III (n = 10) and IV (n = 11) rats received 0.5 ml NRS intravenously and either 0.9% saline (group III) or the IL-Ira (group IV). IL-Ira (1 mg) or 0.9% saline was administered subcutaneously at -1, 1.5, 4, 8, 12, and 18 h after anti-GBM Ab or NRS injection. The effect of IL-lra on the course of anti-GBM Ab GN was studied at two time points, 4 and 24 h. 20 rats (5 from each group) were killed 4 h after anti-GBM Ab or NRS administration. The remaining rats (n = 23) were killed at 24 h. In these rats, 24-h urine and sera were collected for protein and creatinine determination, respectively. The former was quantitated by the sulfosalicylic method ( 19) and the latter by a commercial kit according to the directions of the manufacturer (Sigma Chemical Co., St. Louis, MO).
A second study was performed to determine if a higher dose of the IL-lra could further decrease PMN infiltration at 4 h. Group VI (n = 3) rats were administered a total of 30 mg IL-lra subcutaneously, divided into five doses of 6 mg each at hourly intervals from -1 to 3 h. Control rats (group V, n = 3) were given 0.9% saline. Both groups received 0.5 ml anti-GBM Ab at 0 h and were killed 4 h after Ab administration.
To determine whether the protective effect of IL-1 ra could be overcome by increasing the anti-GBM Ab dose, a third study was performed in which rats were given 1 ml anti-GBM Ab intravenously. Group VII rats (n = 3) were given 0.9% saline subcutaneously at -1, 0, 1, 2, and 3 h after anti-GBM Ab injection, while group VIII rats (n = 3) assayed by an antigen capture ELISA, as described previously (20) . Briefly, samples were sequentially incubated with an affinity-purified rabbit polyclonal Ab raised against human recombinant IL-I ra, biotinylated murine anti-rabbit IgG, and horseradish peroxidase conjugated to avidin. The limit of detection of the assay was 6 ng/ml. All samples were assayed in triplicate.
Quantitation ofanti-GBMAb binding. A paired-label isotope study was performed to ensure that IL-Ira did not interfere with anti-GBM Ab binding. Gamma globulin fractions of the anti-GBM serum and NRS were prepared by precipitation with saturated ammonium sulfate and then were labeled with 125I and '13I, respectively (21) . Mixtures containing 60 Mg of each protein were administered intravenously to six rats. The rats were divided into two groups (n = 3) and received either 0.9% saline or IL-lra subcutaneously, as described above. The rats were killed at 24 h. After perfusion of the kidneys with 0.9% saline through the right ventricle and abdominal aorta, the kidneys were removed and weighed, and the radioactivity was quantitated. Proteinbound counts in the plasma were determined by precipitation in a final concentration of 10% TCA. The specific uptake was calculated as described previously (22 (23) . Sections were incubated with a predetermined dilution of each mAb, followed by fluoresceinated goat anti-mouse IgG that had been absorbed with rabbit and rat IgG. ED-I and LFA-1,B expression were quantitated by counting the number of ED-1 and LFA-lB-staining cells in 25 glomerular cross sections. Quantitation of steady state glomerular mRNA expression. Glomeruli were isolated by sequential sieving through No. 60 and No. 100 mesh wire screens. The glomeruli collected on the No. 200 mesh screen contained < 10% tubular contamination. After washing with 0.9% saline, the glomeruli were homogenized in 4 M guanidine isothiocyanate with a sonicator (Heat Systems-Ultrasonics, Inc., Plainview, NY). The RNA was prepared by cesium chloride centrifugation, was quantitated by its absorption at 260 nm, and then was frozen at -70°C. 2 Mug of glomerular total RNA was hybridized with 105 counts of each [32P]UTP-labeled rat antisense riboprobe at 56°C for 12-14 h.
The preparation of the [32P] UTP-labeled rat riboprobes for IL-10, TNFa, and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (gift of Dr. Ray Wu, Cornell University, Ithaca, NY) has been described previously (24) . Unhybridized RNA was digested with RNase T I (Ambion Inc., Austin, TX) and RNase A (Sigma Chemical Co.) at 30°C for 1 h. The RNase was then digested with proteinase K, 10 mg/ml for 30 min at 37°C. After phenol-chloroform extraction and sodium acetate-ethanol precipitation, the samples were electrophoresed on 6% polyacrylamide gel.
The dried radioactive blots were scanned on a radioanalytic imaging system (AMBIS Inc., San Diego, CA) for 4-6 h. The blot was computer regenerated on the monitor and rectangles were drawn to circumscribe the detected bands. The amount of radioactivity present within each rectangle was determined, corrected for background counts, and normalized to a square centimeter. The data are presented as a ratio of specific mRNA/GAPDH mRNA to ensure a constant quantity of RNA in each sample.
Statistical methods. All data are presented as the mean±SD. Statistical analyses were performed by ANOVA. Then, significant differences were analyzed by comparing individual group means using the unpaired Student's t test. For data that were not normally distributed, analyses were performed by the Wilcoxon rank sum. A P < 0.05 was defined as statistically significant.
Results
Morphology. 4 h after the administration of anti-GBM Ab, the rats developed a diffuse infiltrative/proliferative GN composed predominantly of PMNs which receded by 24 h (Table  I) , leaving a residual mononuclear leukocyte infiltration. The mean number of infiltrating PMNs per glomerulus at 4 h was 9.8±1.9 in the rats treated with saline (group I). The administration of the IL-Ira resulted in a 38.5% decline to 6.0±1.5 PMN/glomerulus (group II, P < 0.001 ) ( Table I) . By comparison, the two groups treated with NRS had 1.0±0.3 (group III) and 1.0±0.3 (group IV) PMN/glomerulus.
Immunofluorescence microscopy. Control rats that were administered NRS with either 0.9% saline (group III) or IL-I ra (group IV) had no evidence of immunofluorescent staining with either anti-rabbit IgG, rat C3, or fibrinogen Abs. In contrast, there were diffuse 4+ linear deposits ofrabbit IgG and rat C3 along the GBM in both groups I and II rats. The staining between these two groups was indistinguishable at both 4 and 24 h. Fibrin deposits were seen within < 5% of the glomerular capillary lumens, with a variation in intensity among capillary loops and glomeruli. There were no differences in glomerular fibrin deposits between groups I and II rats at either 4 or 24 h. Similar results were obtained for rabbit IgG, rat C3, and glomerular fibrin staining for groups V and VI in the two high dose IL-1 ra studies.
Indirect immunofluorescence microscopy staining for ED-1 revealed that the number of monocytes infiltrating the glomerulus was reduced 28.6% from 4.9±0.8 (group I) to 3.5±0.8 (group II) at 4 h with IL-lra treatment (P = 0.002) (Fig. 1, A  and B) . Both values were significantly greater than those in groups III ( 1.2±0.4) and IV ( 1.4±0.4) rats (Table I) . At 24 h, there was an increase in ED-1 staining to 7.5±1.4 cells/glomerulus in rats from group I, which decreased 17.3% to 6.2±1.0 cells/glomerulus in rats treated with IL-1 ra (group II, P <0.001).
The reduction in infiltrating PMNs and macrophages at 4 h was accompanied by a 38.5% reduction in cells expressing LFA-lIl in rats given anti-GBM Ab and treated with IL-Ira ( 10.7±1.6 cells/glomerulus) when compared with those given Ab and control 0.9% saline (16.7±1.9 cells/glomerulus, P = 0.0001) (Fig. 1, C and D) . By comparison, rats in both control groups (III and IV) that received NRS had 1.1±0.4 LFA-l-positive cells/glomerulus (Table I ). The number of cells within the glomerulus expressing LFA-lB at 24 h in group I rats declined from 16.7±1.9 cells/glomerulus to 8.5+1. 1, reflecting a decrease in the number of infiltrating PMNs. Treatment with IL-1 ra resulted in an additional 16% reduction in LFA-I staining in group II rats (7.1 1 l.0, P < 0.003).
There was a constitutive low level immunolabeling for ICAM-l within the endothelial cells ofthe arterioles and intertubular capillaries of the normal kidney. In addition, there was a variable segmental capillary wall staining within the glomerulus. However, the source of ICAM-1 within the glomerulus could not be determined by light microscopy, but has been demonstrated previously by immunoelectron microscopy to arise from endothelial and epithelial cells of Bowman's capsule (1O). Control rats treated with NRS and either 0.9% saline or IL-I ra had a similar pattern and degree ofstaining for ICAM-l at 4 h. By comparison, rats given anti-GBM Ab and 0.9% saline (group I) had increased ICAM-1 staining that decreased with IL-Ira treatment. Fig. 2, A and B are representative photomicrographs ofICAM-1 staining in anti-GBM Ab GN which demonstrate our grading system. The mean glomerular ICAM-1 score for the two control groups treated with NRS was 0.8+0.2, while for those with anti-GBM Ab GN (Fig. 3) , it was 2.5±0.2 (range 2.3-2.7). The administration of IL-Ira decreased the glomerular ICAM-l score to 2.0±0.2 (P < 0.05) (range 1.2-2.4), although two rats had scores (2.3, 2.4) that crossed over into the group that was administered anti-GBM Ab and 0.9% saline. However, by 24 h, the glomerular ICAM-1 score had segregated between the two groups (Fig. 3) . There was an increase in the mean score of group I rats to 3.1±0.2 (range 2.8-3.2) compared with 2.5±0.1 (P = 0.0001) with IL-lra treatment (range 2.4-2.7). Ag/kidney, which was similar to control rats treated with 0.9% saline (0.329±0.013 Atg/kidney) at the 60-mg test dose used.
Functional studies. The serum creatinine measured at 24 h was similar among the four groups as rats with anti-GBM Ab GN did not develop azotemia at this early time point. The serum creatinine in the two groups with anti-GBM Ab GN were 0.5±0.1 (group I) and 0.4±0.1 (group II) mg/dl, while the values in control rats were 0.4±0.1 (group III) and 0.4±0.1 (group IV) mg/dl.
The 24-h urinary protein excretion in all rats before the experiment was < 5 mg. Rats in groups III and IV remained free of proteinuria (< 5 mg/24 h). By comparison, rats given anti-GBM Ab and 0.9% saline (group I) had urinary protein excretion of 147±34 mg/ 24 h. IL-1 ra treatment (group II) produced a reduction in proteinuria to 75±25 mg/24 h (P < 0.002).
Plasma concentration ofIL-Ira. At 4 h, the plasma IL-1 ra concentrations were 2,659±1,636 and 1,984±1,059 ng/ml in groups II and IV (P = NS), respectively, which declined to 87±88 and 27±22 ng/ml, respectively, at 24 h. There was a significant difference in plasma IL-I ra concentrations between the 4-and 24-h values. These differences may be attributed to the schedule of IL-Ira administration in which the 4-h plasma concentration was determined 2.5 h after the last IL-lra dose, while the 24-h plasma level reflects a dose given 6 h earlier. IL-Ira was not detected in the plasma of the saline-injected groups I and III rats at either time point.
Effect ofIL-i ra on steady state glomerular mRNA expression. The steady state IL-I3/GAPDH mRNA ratio in groups I (1.49±0.44) and II (1.27±0.40) was similar at 4 h, but was no longer detected at 24 h. IL-I 3 transcripts were not detectable in groups III and IV rats at either 4 or 24 h. Similarly, there were no detectable transcripts for TNFa in groups III or IV rats at either 4 or 24 h. By comparison, group I rats had a TNFa/ GAPDH steady state mRNA ratio of 0.27±0.05 at 4 h after anti-GBM Ab administration, which became undetectable by 24 h. This ratio was not significantly different from rats treated with IL-Ira (0.24±0.05).
High dose IL-Ira study. Two additional studies were performed to examine the IL-I ra effect on PMN infiltration at 4 h.
In both studies, IL-Ira was administered hourly with an increase in the total dose to 30 mg, 15-fold greater than the cumulative 4-h dose in the first study (2 mg). The dose of anti-GBM Ab was doubled to 1.0 ml in the third study. Despite a 16-fold increase in the plasma IL-Ira concentration to 39,970±5,215 ng/ml in the second study (standard 0.5 ml anti-GBM Ab), there was no additional benefit afforded by IL-Ira (Table I ). The mean number of PMNs infiltrating each glomerulus decreased 32.4% to 6.2± 1.0 from 9.2±1.4 (P < 0.002) with the higher dose of IL-Ira. The amelioration of macrophage infiltration also did not improve with the higher dose ofIL-I ra. There was a 25% decrease in ED-I staining cells from 4.4± 1.0 to 3.3±1.1 (P = 0.01). The administration ofa higher dose ofthe anti-GBM Ab ( 1 ml) resulted in an increase in PMN infiltration at 4 h and negated the protective effect ofIL-I ra on PMN infiltration (Table I), despite a plasma IL-Ira concentration of 42,303±9,809 ng/ml in group VIII rats. Interestingly, group VII rats treated with 0.9% saline had plasma IL-Ira concentrations of 15±4 ng/ml, indicating the presence of an endogenous IL-Ira response. The number of PMNs infiltrating the glomerulus increased twofold with a doubling of the anti-GBM Ab administered (Table I ). The intensity of the inflammatory response appeared to have overshadowed the benefit ofthe IL-1 ra noted with the lower dose model, since there were no differences in the number of PMNs infiltrating the glomerulus at 4 h between those that had received IL-I ra (19 [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] h (29).
After margination, leukocyte integrins including LFA-1, Mac-l (CDl lb/CD18), and p150,95 (CDl lc/CD18), which are constitutively expressed as inactive proteins, are qualitatively and quantitatively activated. Once activated, leukocytes are able to bind to their endothelial adhesins. Of the three leukocyte integrins, the interaction between LFA-I and its ligand, ICAM-1, has been the most extensively studied. The availability of mAbs to LFA-1 and ICAM-1 enabled us to study this interaction in anti-GBM Ab GN. The binding of LFA-1 and ICAM-1 results in adhesion and migration of PMN through the endothelium (33) . In contrast to ELAM-1, ICAM-1 appears within 2-3 h, although its peak expression is not seen until 24 h after stimulation by IL-1 (34) . This latter finding may account for the heterogeneity of glomerular ICAM-1 expression at 4 h in which the score of two rats administered IL-1 ra crossed over into group I, while there was complete segregation of the ICAM-1 scores at 24 h.
The decline in glomerular ICAM-1 expression was associated with a decrease in glomerular leukocyte infiltration at 4 and 24 h in rats treated with IL-1ra. This is consistent with a previous study demonstrating attenuation ofglomerular leukocyte infiltration in anti-GBM Ab GN with the administration of a neutralizing Ab to ICAM-1 ( 35 ) . Our data are also consistent with in vitro observations in which pretreatment of endothelial cells with IL-1 ra blocks the adhesion ofPMN to endothelial cells (36) . However, our data differ from that reported by Mulligan et al. (37) , in which IL-Ira did not affect glomerular neutrophil infiltration or urinary protein excretion. This discrepancy likely reflects differences in the severity of anti-GBM Ab GN as well as in the frequency and quantity of IL-1 ra administered. The latter may be of critical importance since a discordance between the binding of IL-1 ra and suppression of IL-1 activity has been noted. To achieve a therapeutic effect, > 95% of IL-1 receptors must be blocked, since IL-1 activity can be elicited by binding to < 5% of its receptors (38) . The quantity of IL-1 ra administered in our low dose study exceeds that reported by Mulligan and colleagues by fivefold. More importantly, our dosing regimen insured high plasma concentrations of IL-1 ra within the initial 4-6 h, when IL-1 activity is highest.
A 15-fold increase in the cumulative dose of IL-1 ra administered by 4 h resulted in an approximate 16-fold increase in plasma IL-1ra levels. However, an additional benefit, as assessed by a further decrease in the number ofinfiltrating PMNs and monocytes/macrophages, was not seen. The incomplete protective effect of IL-lra could be anticipated, since other inflammatory mediators, including TNFa (32), C5a (39), platelet activating factor (40) , and leukotriene B4 (41, 42) ), promote PMN adhesion to endothelial cells through both ICAM-l-dependent and -independent mechanisms. Indeed, we demonstrated that steady state mRNA levels ofTNFa were unaffected by the administration of IL-lra. This is consistent with the inability of IL-lra to suppress serum TNF activity after LPS administration (43) . The absence of an IL-lra effect on TNFa expression is of significance, since TNF can activate PMN to upregulate CD18-associated proteins, while IL-l cannot (44, 45). Finally, additional mechanisms for PMN adherence to endothelium exist, since a combination of anti-ELAM-l and anti-ICAM-l was only 80% effective in blocking PMN adhesion to endothelial cells in vitro (46) . Several ligands that are independent ofIL-1 activation are being defined. They include intracellular adhesion molecule-2 (47) and platelet activationdependent granule external membrane protein (PADGEM). The latter molecule is of interest since its expression by endothelial cells is upregulated within seconds to minutes by the complement proteins C5b-9 (48). PADGEM expression precedes that of ELAM-1 (49) and it can promote the adhesion of PMN to the endothelium (50) . Thus, PADGEM and its yet to be defined ligand may be one of the earliest mechanisms for PMN margination.
In summary, our results demonstrated an increase in ICAM-1 expression 4 h after anti-GBM Ab administration. This increase was in part due to IL-1, since treatment with the IL-1ra decreased ICAM-1 expression, which was associated with a 30-40% decline in PMN and monocyte infiltration. These histopathologic changes were associated with a 50% reduction in 24-h urinary protein excretion. Although Abs directed towards ICAM-1 may be of greater efficacy in preventing leukocyte infiltration and proteinuria, the lack ofimmunogenicity of this recombinant human protein suggest a potential therapeutic role for this agent in anti-GBM Ab GN.
